215 related articles for article (PubMed ID: 18291415)
1. Yeast cytosine deaminase mutants with increased thermostability impart sensitivity to 5-fluorocytosine.
Stolworthy TS; Korkegian AM; Willmon CL; Ardiani A; Cundiff J; Stoddard BL; Black ME
J Mol Biol; 2008 Mar; 377(3):854-69. PubMed ID: 18291415
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of enzyme and pathway engineering strategies for 5FC-mediated suicide gene therapy applications.
Johnson AJ; Ardiani A; Sanchez-Bonilla M; Black ME
Cancer Gene Ther; 2011 Aug; 18(8):533-42. PubMed ID: 21394105
[TBL] [Abstract][Full Text] [Related]
3. Role of glutamate 64 in the activation of the prodrug 5-fluorocytosine by yeast cytosine deaminase.
Wang J; Sklenak S; Liu A; Felczak K; Wu Y; Li Y; Yan H
Biochemistry; 2012 Jan; 51(1):475-86. PubMed ID: 22208667
[TBL] [Abstract][Full Text] [Related]
4. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine.
Hirschowitz EA; Ohwada A; Pascal WR; Russi TJ; Crystal RG
Hum Gene Ther; 1995 Aug; 6(8):1055-63. PubMed ID: 7578418
[TBL] [Abstract][Full Text] [Related]
5. Product release is rate-limiting in the activation of the prodrug 5-fluorocytosine by yeast cytosine deaminase.
Yao L; Li Y; Wu Y; Liu A; Yan H
Biochemistry; 2005 Apr; 44(15):5940-7. PubMed ID: 15823054
[TBL] [Abstract][Full Text] [Related]
6. Alanine-scanning mutagenesis reveals a cytosine deaminase mutant with altered substrate preference.
Mahan SD; Ireton GC; Stoddard BL; Black ME
Biochemistry; 2004 Jul; 43(28):8957-64. PubMed ID: 15248753
[TBL] [Abstract][Full Text] [Related]
7. Bacterial cytosine deaminase mutants created by molecular engineering show improved 5-fluorocytosine-mediated cell killing in vitro and in vivo.
Fuchita M; Ardiani A; Zhao L; Serve K; Stoddard BL; Black ME
Cancer Res; 2009 Jun; 69(11):4791-9. PubMed ID: 19487291
[TBL] [Abstract][Full Text] [Related]
8. Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression.
Perez OD; Logg CR; Hiraoka K; Diago O; Burnett R; Inagaki A; Jolson D; Amundson K; Buckley T; Lohse D; Lin A; Burrascano C; Ibanez C; Kasahara N; Gruber HE; Jolly DJ
Mol Ther; 2012 Sep; 20(9):1689-98. PubMed ID: 22547150
[TBL] [Abstract][Full Text] [Related]
9. Intracellular prodrug gene therapy for cancer mediated by tumor cell suicide gene exosomes.
Altanerova U; Jakubechova J; Benejova K; Priscakova P; Repiska V; Babelova A; Smolkova B; Altaner C
Int J Cancer; 2021 Jan; 148(1):128-139. PubMed ID: 32621791
[TBL] [Abstract][Full Text] [Related]
10. Escherichia coli cytosine deaminase: Structural and biotechnological aspects.
Vosough P; Vafadar A; Naderi S; Alashti SK; Karimi S; Irajie C; Savardashtaki A; Taghizadeh S
Biotechnol Appl Biochem; 2024 Feb; 71(1):5-16. PubMed ID: 37743549
[TBL] [Abstract][Full Text] [Related]
11. The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies.
Hamstra DA; Lee KC; Tychewicz JM; Schepkin VD; Moffat BA; Chen M; Dornfeld KJ; Lawrence TS; Chenevert TL; Ross BD; Gelovani JT; Rehemtulla A
Mol Ther; 2004 Nov; 10(5):916-28. PubMed ID: 15509509
[TBL] [Abstract][Full Text] [Related]
12. Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy.
Kazlauskas A; Darinskas A; Meškys R; Tamašauskas A; Urbonavičius J
BMC Cancer; 2019 Mar; 19(1):197. PubMed ID: 30832616
[TBL] [Abstract][Full Text] [Related]
13. Cytosine deaminase-producing human mesenchymal stem cells mediate an antitumor effect in a mouse xenograft model.
You MH; Kim WJ; Shim W; Lee SR; Lee G; Choi S; Kim DY; Kim YM; Kim H; Han SU
J Gastroenterol Hepatol; 2009 Aug; 24(8):1393-400. PubMed ID: 19486256
[TBL] [Abstract][Full Text] [Related]
14. Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice.
Kucerova L; Matuskova M; Pastorakova A; Tyciakova S; Jakubikova J; Bohovic R; Altanerova V; Altaner C
J Gene Med; 2008 Oct; 10(10):1071-82. PubMed ID: 18671316
[TBL] [Abstract][Full Text] [Related]
15. Suicide gene therapy with the yeast fusion gene cytosine deaminase/uracil phosphoribosyltransferase is not enough for pancreatic cancer.
Fogar P; Navaglia F; Basso D; Greco E; Zambon CF; Fadi E; Falda A; Stranges A; Vannozzi F; Danesi R; Pedrazzoli S; Plebani M
Pancreas; 2007 Oct; 35(3):224-31. PubMed ID: 17895842
[TBL] [Abstract][Full Text] [Related]
16. Random mutagenesis and selection of Escherichia coli cytosine deaminase for cancer gene therapy.
Mahan SD; Ireton GC; Knoeber C; Stoddard BL; Black ME
Protein Eng Des Sel; 2004 Aug; 17(8):625-33. PubMed ID: 15381761
[TBL] [Abstract][Full Text] [Related]
17. Exogenous cytosine deaminase gene expression in Bifidobacterium breve I-53-8w for tumor-targeting enzyme/prodrug therapy.
Hidaka A; Hamaji Y; Sasaki T; Taniguchi S; Fujimori M
Biosci Biotechnol Biochem; 2007 Dec; 71(12):2921-6. PubMed ID: 18159091
[TBL] [Abstract][Full Text] [Related]
18. Transduction of yeast cytosine deaminase mediated by HIV-1 Tat basic domain into tumor cells induces chemosensitivity to 5-fluorocytosine.
Lee H; Ryu J; Kim KA; Lee KS; Lee JY; Park JB; Park J; Choi SY
Exp Mol Med; 2004 Feb; 36(1):43-51. PubMed ID: 15031670
[TBL] [Abstract][Full Text] [Related]
19. Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts.
Kievit E; Nyati MK; Ng E; Stegman LD; Parsels J; Ross BD; Rehemtulla A; Lawrence TS
Cancer Res; 2000 Dec; 60(23):6649-55. PubMed ID: 11118048
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of genetically engineered stem cells expressing yeast cytosine deaminase in lung cancer brain metastases via their tumor-tropic properties.
Yi BR; Kim SU; Kim YB; Lee HJ; Cho MH; Choi KC
Oncol Rep; 2012 Jun; 27(6):1823-8. PubMed ID: 22426744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
